Back to All NewsFiller Hypersensitivity Post COVID-19 Illness
Posted By American Med Spa Association, Friday, August 20, 2021
Share
The Journal of Cosmetic Dermatology recently published a case report examining hypersensitivity reactions to hyaluronic acid (HA) dermal filler after COVID-19 infection.
The incidence rate (IR) of a delayed-type hypersensitivity reaction is cited as between 0.3% and 4.25%.
The exact cause of delayed-onset reactions is not yet understood. Factors that may contribute to these incidents include infections, filler properties, trauma, and injection technique, with multiple treatment episodes and links to influenza‐like illness.
Study authors examined the June 2020 case of a 22-year-old female with a raspberry sensitivity who underwent a nonsurgical rhinoplasty procedure using HA dermal filler (Perfectha Subskin; Sinclair Pharma) to adjust the view of her dorsal hump. At the time of the procedure, no adverse events (AEs) were reported.
Filler was injected using a 30G x 8 mm 0.3 mL BD Microfine needle to reduce injection trauma and improve precision. Filler placement was made to the area of the nasal radix with the needle perpendicular to the bone, depositing 0.5 mL in 0.1 mL increments that were 5 mm apart, in line with documented techniques. Further placement was made at the nasal tip, depositing 0.3 mL in 0.1 mL. Injection volumes totaled 0.8 mL. The patient underwent the same procedure again in July 2020 with no reported AEs.
In October 2020, the patient received a COVID-19 diagnosis and had cold-like symptoms. Three weeks after diagnosis, in November, she exhibited the following AEs: edema, induration, erythema, mild associated tenderness, and a tight feeling in the area around the radix.
Read more at Dermatology Times >>
The incidence rate (IR) of a delayed-type hypersensitivity reaction is cited as between 0.3% and 4.25%.
The exact cause of delayed-onset reactions is not yet understood. Factors that may contribute to these incidents include infections, filler properties, trauma, and injection technique, with multiple treatment episodes and links to influenza‐like illness.
Study authors examined the June 2020 case of a 22-year-old female with a raspberry sensitivity who underwent a nonsurgical rhinoplasty procedure using HA dermal filler (Perfectha Subskin; Sinclair Pharma) to adjust the view of her dorsal hump. At the time of the procedure, no adverse events (AEs) were reported.
Filler was injected using a 30G x 8 mm 0.3 mL BD Microfine needle to reduce injection trauma and improve precision. Filler placement was made to the area of the nasal radix with the needle perpendicular to the bone, depositing 0.5 mL in 0.1 mL increments that were 5 mm apart, in line with documented techniques. Further placement was made at the nasal tip, depositing 0.3 mL in 0.1 mL. Injection volumes totaled 0.8 mL. The patient underwent the same procedure again in July 2020 with no reported AEs.
In October 2020, the patient received a COVID-19 diagnosis and had cold-like symptoms. Three weeks after diagnosis, in November, she exhibited the following AEs: edema, induration, erythema, mild associated tenderness, and a tight feeling in the area around the radix.
Read more at Dermatology Times >>
